

IN THE CLAIMS:

Please rewrite the pending claims as follows:

02 2. (Currently Amended) An isolated infectious Respiratory Syncytial Virus (RSV) particle containing an RSV RNA comprising a binding site specific for an RNA-directed RNA polymerase operatively linked to an RSV RNA comprising sequences encoding antigenic polypeptides of both RSV-A and RSV-B.

13. (Previously Amended) A vaccine comprising a chimeric Respiratory Syncytial Virus (RSV) the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of an RSV and a pharmaceutically acceptable carrier.

03 18. (Currently Amended) The vaccine of Claim 13 in which the mRNA coding sequence encodes G and F polypeptides genes of both Respiratory Syncytial Virus A and Respiratory Syncytial Virus B.

25. (Previously Added) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a L gene mutation.

26. (Previously Added) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a deletion of M2-ORF1 and/or SH-ORF2.

REMARKS

Claims 1-26 are pending. Claims 2, 13, 18, 25 and 26 are under active consideration due to the restriction requirement dated November 17, 1999. Claim 2 has been amended herein to merely correct technical informalities.

Claim 18 has been amended to more clearly point out what Applicants consider as the invention. Support for the amendment to claim 18 can be found, e.g., on page 7, lines 1-4 of the application as filed. Thus, no new matter has been introduced.

The amendments to the claims merely clarify the subject matter intended to be claimed, and in no way narrow the scope of the claims.

1. The Objection to Claim 2 Should Be Withdrawn

Claim 2 is objected to because it recites that the RSV RNA comprises sequences instead of a sequence. In view of Applicants' amendment, the objection should be withdrawn.